Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Spurred by “the rise of Chinese power,” Japanese automakers Honda and Nissan announced Monday that they are in talks to merge.
The secret ingredients to Lego’s success? A clutch of licensing deals and finding ways to sell Lego sets to kids well over the age of 30.
Though small compared to each company’s total workforces, work stoppages have set uncomfortable precedents for management.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
The offer would put an 83% premium on Soho’s Wednesday closing price and comes a year after it had to close off admissions in three cities.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Don’t get too excited for cheaper Taylor Swift tickets: The rules just force sellers to present all the extra fees upfront.
Sometimes, markets don’t need breathless buzzwords to get excited. Sometimes, “marginally encouraging” will do. Ask Pfizer shareholders.
It’s part of the EU’s goal to build its own spacefaring infrastructure, reducing its dependence on US private companies.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.